Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
FELINE CALICIVRUS, STRAIN F9 LIVE ATTENUATED, FELINE HERPES VIRUS TYPE 1, STRAIN G2620A LIVE ATTENUATED, FELINE PANLEUCOPENIA VIRUS, STRAIN MW-1 LIVE ATTENUATED
Intervet Ireland Limited
QI06AD04
FELINE CALICIVRUS, STRAIN F9 LIVE ATTENUATED, FELINE HERPES VIRUS TYPE 1, STRAIN G2620A LIVE ATTENUATED, FELINE PANLEUCOPENIA VI
Unknown
Lyophilisate and solvent for suspension for injection
POM
Feline
Feline panleucopenia virus / parvovirus vaccine + Feline rhinotracheitis virus vaccine + Feline cal
Immunological - Live Vaccine
Authorised
2007-02-28
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Nobivac Tricat Trio, lyophilisate and solvent for suspension for injection, for cats. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Per dose of 1 ml: ACTIVE SUBSTANCES: Lyophilisate live attenuated feline calicivirus, strain F9: 4.6 log 10 PFU 1 ; live attenuated feline herpes virus type 1, strain G2620A: 5.2 log 10 PFU 1 ; live attenuated feline panleucopenia virus, strain MW-1: 4.3 log 10 CCID 50 2 1 PFU: Plaque-Forming Units 2 CCID 50: Cell Culture Infective Dose 50% EXCIPIENTS: For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Lyophilisate and solvent for suspension for injection. Off-white lyophilisate 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Cats. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Active immunisation of cats: − to reduce the clinical signs caused by infection with feline calicivirus (FCV) and feline herpes virus type 1 (FHV), − to prevent the clinical signs, leucopenia and virus excretion caused by infection with feline panleucopenia virus (FPLV). Onset of immunity: for FCV and FHV: 4 weeks; for FPLV: 3 weeks. Duration of immunity for FCV and FHV: 1 year, for FPLV: 3 years. 4.3 CONTRAINDICATIONS See point 4.7 IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 31/01/2014_ _CRN 7016594_ _page number: 1_ 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Maternal antibodies, which may persist up to the age of 9-12 weeks, can have a negative influence on the efficacy of vaccination. In the presence of maternal antibodies, vaccination may not completely prevent the clinical signs, leucopenia and virus excretion following an FPLV infection. In such cases where a relatively high level of matern Read the complete document